Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
List view / Grid view
Filter the results
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
Research into the M2 proton channel of influenza B has revealed its structure, which the team hope can aid in the development of targeted therapeutics to block the channel and treat the condition.
A study in mice has found that a compound modelled on a protein found in bananas safely protects against multiple strains of the influenza virus.
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
An mRNA vaccine has been developed which has elicited strong immune responses in mice in the presence of maternal antibodies.
A new double-layered nanoparticle vaccine protected mice against six strains of the flu and may provide the basis for the first universal vaccine against seasonal influenza, according to research.